Latest News for: antibodies

Edit

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Nasdaq Globe Newswire 03 Apr 2025
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.  ... .
Edit

Nitrase Therapeutics Presents Preclinical Data from Multiple Studies Demonstrating Its Antibody Prevents Pathological Spread of ...

Nasdaq Globe Newswire 01 Apr 2025
- NDC-0524 is a First-in-class Monoclonal Antibody with High Selectivity for Nitrated Alpha-synuclein (nSyn) and is Expected to Begin a Randomized Phase 1/2a Trial in the Fourth Quarter of 2025 ... .
Edit

Data Showcasing ALZpath's Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer's Disease Research and Diagnosis

PR Newswire 01 Apr 2025
Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use - Featured in Seven Oral Presentations and Two Posters .
Edit

Q3 2025 Earnings Presentation (ImmunoPrecise Antibodies Ltd)

Public Technologies 31 Mar 2025
). FY 2025 Q3. Earnings Presentation. March 28, 2025 . ir.ipatherapeutics.com . NASDAQ. IPA. Presented by Dr. Jennifer Bath, IPA CEO. Fiscal Year 2025 Q3 Business Update ... $8.8 Million (USD) ... Capital raise ... De novo antibody design ... 10 ... ImmunoPrecise Antibodies Ltd.
Edit

Cancer Monoclonal Antibodies Market Poised for Strong Growth, Projected to Expand at a 10% CAGR ...

GetNews 31 Mar 2025
Cancer Monoclonal Antibodies Market by Type (Humanized Antibodies, Chimeric Antibodies, Murine Antibodies) ...Continuous innovations in monoclonal antibody technology, including bispecific ...
Edit

Q3 2025 Earnings Transcript (ImmunoPrecise Antibodies Ltd)

Public Technologies 31 Mar 2025
ImmunoPrecise Antibodies ... IMMUNOPRECISE ANTIBODIES LTD ... IMMUNOPRECISE ANTIBODIES LTD ... Good morning, ladies and gentlemen, and thank you for joining us today for ImmunoPrecise Antibodies Third Quarter Fiscal Year 2025 Earnings Call.
Edit

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Nasdaq Globe Newswire 31 Mar 2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - ... .
Edit

IMMUNOPRECISE ANTIBODIES LTD. MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2025 (Form 6-K) (ImmunoPrecise Antibodies Ltd)

Public Technologies 28 Mar 2025
IMMUNOPRECISE ANTIBODIES LTD ... The following Management's Discussion and Analysis ("MD&A") should be read in conjunction with the unaudited condensed interim consolidated financial statements of ImmunoPrecise Antibodies Ltd.
Edit

Ocean Biomedical Announces Grant on Patent Right for�Bispecific�Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor ...

Nasdaq Globe Newswire 28 Mar 2025
OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, ...
×